Previous close | 14.07 |
Open | 14.09 |
Bid | 13.88 x 900 |
Ask | 15.00 x 800 |
Day's range | 14.00 - 14.42 |
52-week range | 13.62 - 21.95 |
Volume | |
Avg. volume | 463,862 |
Market cap | 5.062B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.74 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.57 |
VAUGHAN, Ontario, April 15, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of th
VAUGHAN, Ontario, March 27, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in Boston, April 5-8, 2024.
VAUGHAN, Ontario, February 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company’s 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling’s appointment, the Board has been temporar